Screening of Effective siRNA Sequence Targeting to HBV and Antiviral Research in vivo

• 作 者: ZHANGYa-li;CHENGTong;CAIYi-Jun;ZHANGTao;WEILI-hua;YANGBing-chun;ZHAGNJun;XIANing-shao;
• 机 构: National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sci
• 出 处: 2008病毒性肝炎成就与挑战国际研讨会(International Confernece on Viral Hepati
• 发表日期: 2008年期

　　Chronic hepatitis B virus (HBV) infection is one of the leading causes of liver cirrhosis and hepatocellular carcinoma (HCC).Current treatment strategies of HBV infection including the use of interferon (IFN)-c and nucleotide analogues such as lamivudine and adefovir have met only partial success.Therefore, it is necessary to develop more effective antiviral therapies that can clear HBV infection with fewer side effects.RNA interference (RNAi), by which a small interfering RNA (siRNA) induces the gene silence at a posttranscriptional level, has the potential of treating HBV infection.